ITeos Therapeutics Inc
ITOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$448.68M
Close$
$2.28
77.5% downside
Current Fair Value
77.5% downsideOvervalued by 77.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $448.68 Million |
|---|---|
| Enterprise Value | $247.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 1.49 |
| Outstanding Shares | 43,564,573 |
Return
| Return on Equity | -40.99% |
|---|---|
| Return on Assets | -32.49% |
| Return on Invested Capital | -36.80% |
Valuation & Multiples
| P/E Ratio | -2.82 |
|---|---|
| PEG | -0.28 |
| Price to Sales | - |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.22 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8337▼ 524.62% |
|---|---|
| Total Calls | 733,000▲ 503.79% |
| Total Puts | 611,100▼ 17.21% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.80%▲ 1.31% |
|---|---|
| Total Invested | $377.01M▲ 70.83% |
| Investors Holding | 141▲ 7.00% |
ESG Score
No data
About ITeos Therapeutics Inc
62 employeesiTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep under...